Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check.
Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin.
The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors and electronic health records. Novo Nordisk also intends to make an equity investment in Amalgam.
Get the full story at our sister site, Drug Delivery Business News.